The landscape of weight loss management is rapidly shifting beyond the initial dominance of Ozempic and Wegovy, leading to the emergence of next-generation treatments.
Among these new weight loss treatments is retatrutide, developed by Eli Lilly. Retatrutide has been positioned as a potential ‘new wave’ therapy with initial clinical data suggesting superior weight loss results compared with Wegovy.
The growing popularity of GLP-1 receptor agonists will have a significant impact on the pharmaceutical sector with commercial and IP considerations becoming just as important as clinical efficacy.
Check out the rest of the feature here
